Our Leadership

Aspira Women's Health is dedicated to the discovery, development, and commercialization of AI-powered tests to aid in the diagnosis of gynecologic diseases, starting with ovarian cancer. 

Executive Leadership Team

Mike Buhle

Mike Buhle

CEO

Mike Buhle joined Aspira Women’s Health in January 2025, bringing more than 25 years of leadership experience across the clinical and life sciences sectors. He has specialized in business development, marketing, operations, and strategic partnerships, with deep expertise in women’s health, oncology, and innovative diagnostic and laboratory technology solutions.

Before joining Aspira, Mike held executive roles at Biovision Diagnostics, Congenica, and Danaher Corporation, where he successfully drove market share growth, launched cutting-edge technologies, and built high-performing teams.

Mike earned his Bachelor’s Degree in Business Management from Clarke University and is passionate about advancing technology and clinical solutions to improve patient outcomes.

jstrahley

John Strahley

CFO

John is a financial services professional with experience in both operational and investment roles, helping emerging growth and closely-held companies execute.  He has served as CFO of several life science companies including IsoPlexis Corporation, responsible for strategic planning and financial management.  At Iso, John built scalable financial capabilities, raised debt and equity, and led its IPO.  John previously served as a Managing Director at Ironwood Capital, responsible for originating and structuring debt and equity investments in early-stage and privately-held companies.  In this role, he worked closely with portfolio company management teams to build value, focused on executing strategy, operations and fund raising.  John was also a Senior Vice President at Webster Bank with increasing responsibilities in the commercial bank and in credit and risk functions.  He began his career as a certified public accountant.

 

John earned a bachelor’s degree in accounting from Western Connecticut State University and an MBA from the University of Connecticut.

1710513138411

Todd Pappas, Ph.D.

Chief Science Officer

Dr. Pappas brings 25 years of experience in research and product development across oncology and infectious disease. He has held key leadership roles in clinical research, regulatory affairs, and diagnostic innovation, driving advancements in biomarker data collection, machine learning integration, and point-of-care diagnostics.

Before joining Aspira Women’s Health, Dr. Pappas served as Vice President of Clinical and Regulatory Affairs at Reliant Immune Diagnostics, where he developed clinical research strategies and regulatory frameworks for software-integrated diagnostic tests. He also led clinical research initiatives at Everlywell, spearheaded breast cancer prognostics as Chief Science Officer at Delphi Diagnostics, and directed R&D efforts in biodefense and bio-surveillance at Luminex, managing over $14M in extramural grants.

Dr. Pappas has a BS in Biology from Loyola Marymount University, MS in Biology from California State University, and a PhD in Biomedical Science from the University of Texas Medical Branch.

MicrosoftTeams-image (34)[27]

Michelle Snider

Senior Vice President of Commercialization and Integration

Michelle Snider brings over 15 years of expertise in women’s healthcare and diagnostics. As Senior Vice President of Commercial Strategy and Operations at Aspira Women’s Health, she leads initiatives to drive growth and innovation in the field.

Before rejoining Aspira, Michelle was Vice President of Market Enablement/Sales Strategy at Sema4 Genomics, overseeing women’s health commercial strategy. She also held leadership roles at Sonic Reference Laboratory, Myriad, and Aspira, playing a key role in the development and launch of Ova1®.

Michelle holds a degree in International Business from The University of Texas at San Antonio and is dedicated to advancing women’s health diagnostics.

photo1

Matt Ramey

Senior Vice President of Commercial Operations and Corporate Accounts

With over 16 years of experience in laboratory diagnostics, Matt Ramey is responsible for driving strategic partnerships, commercial growth, and national alliances at Aspira Women’s Health. Before joining Aspira, Matt led business development at Sema4/GeneDx, forging key partnerships with government and private entities and expanding the company’s genetic testing portfolio. Prior to that, he managed regional sales teams at Clinical Pathology Labs, spearheaded new market penetration strategies, and secured high-value contracts with healthcare organizations.

Matt holds a Bachelor of Arts in Biology from the University of Texas at Austin and is committed to advancing diagnostic solutions that improve patient outcomes in women’s health.

Board of Directors

Jack Fraser 800-800
Jack Fraser - Chairman

Jack Fraser is the co-founded and co-portfolio manager of the Seamark Capital Fund, a growth equities asset-management firm. Mr. Fraser and his partner founded Seamark 25 years ago after a successful institution investment advisory career at Friess Associates, CS First Boston, and Merrill Lynch Capital Markets.

Mr. Fraser earned his B.S. in Business Administration from Bowling Green State University and his M.B.A. in Finance from The Ohio State University.

Dr Jeffrey Cohen 800-800
Dr. Jeffrey Cohen

Dr. Cohen is a serial disrupter and entrepreneur in the medical and life science fields. His more than four decades as a practicing urologist with a specialty in oncology, several year tenure as President and CEO of a >500 bed quaternary hospital in a high needs community, and leadership position with one of the largest integrated health networks in the nation, have given him a 360 degree understanding of the economic, clinical, and social issues that impact the American health care system.

As a physician Dr. Cohen has developed and introduced several technologies and procedures to urology such as laser lithotripsy, fiber optic-based endoscopy, piezoelectric biplanar transrectal ultrasound and cryosurgery that have transformed the field and saved lives. He currently holds over 30 patents in the US for these novel discoveries.

As a private practice owner and hospital administrator Dr. Cohen has piloted and scaled approaches to patient management and treatment that create economies of scale and skill.

As an entrepreneur and venture capitalist he has helped technology and life science start-ups develop and market products that lead to better outcomes and save time and money for the health care system.

Dr. Cohen currently serves as CEO of one of those companies, ChemImage, where molecular imaging technology is redefining what is possible in both the biomedical and surgical fields and in threat detection systems.

He also leads Innovation for Allegheny Health Network where he was the driving force behind a joint venture with Innovation Works to create AlphaLab Health, a biotech and life sciences Accelerator based in Bellevue, PA. That venture is part of a larger program led by Dr. Cohen to breathe new life into closed core community institutions and physical assets to support community needs and drive economic growth.

Dr. Cohen understands disruption has uneven consequences and is actively working to make sure that the disruption underway in health care not only creates new value, but also uplifts the communities and individuals left in the wake of that change. His work and passion center around leading the transition from a sickness system to a true health care system to create more opportunity for everyone. This coincides with his family’s deep commitment to the economic and cultural health of his beloved City of Pittsburgh where they participate in several philanthropic organizations to support the continued progress of the region.

BOD
Ellen Beausang

Ms. Beausang has served in executive leadership at BioReference Health, a leading provider of innovative and tailored laboratory test solutions, for over five years, and has held the role of Chief Commercial Officer since 2022. In this capacity, she leads the commercial and product franchise teams, overseeing sales, marketing, training, and strategic direction to drive growth and strengthen BioReference’s portfolio of diagnostic solutions.

With more than 25 years of experience in the pharmaceutical and diagnostics industries, Ms. Beausang has a proven track record of building high-performing teams and developing best-in-class products and services. Before joining BioReference, she held senior leadership roles at Pfizer Pharmaceuticals, Thermo Fisher Diagnostics, and Quest Diagnostics, where she most recently served as Executive Director for Oncology, managing go-to-market strategy and product development.

Ellen holds an M.A. from Seton Hall University and a dual B.S. in Sociology and Psychology.

Cindy 800-800
Cynthia Hundorfean

Cynthia Hundorfean is an innovative and trusted executive who has worked in bold strokes to get health care right for patients, members, communities, and clinicians. She has a record of delivering explosive growth through transformational partnerships, strategic acquisitions, and organic growth strategies, all built on a foundation of unwavering commitment to high-quality, affordable care, and high-performing organizational culture.

She is a Sr. Partner of The CEO Advisory Network, a team of highly accomplished prior CEO’s and COOs of major nonprofit health systems across the US, with a passion for assisting today’s forward-looking CEO’s and senior executives in leading their organizations during these transformational times.

Recently, Cynthia served as the Chief Living Health Development Officer at Highmark Health, one of the largest integrated finance and delivery networks in the nation, and worked to better connect payers, providers, tech innovations, and community organizations to create a more proactive, personalized, and cost-effective health ecosystem across the organization’s national operations.

Previously, she served as the President and CEO of Allegheny Health Network (AHN), the health system fully owned by Highmark Health with 23,000+ employees, 2,500+ aligned physicians, 14 hospitals, and 300+ clinical locations, generating over $4B in annual revenue. After taking the helm in 2016, she orchestrated a return to profitability in 16 months, moving the system from a $32.6M in loss to a net profit of $51.1M. She led strategic cost reductions and improved profitability driven by a transformation to team-based care, consolidation of physical sites, and an aggressive move to value based models with considerable up-side risk.

Prior to AHN, Cynthia served as the Chief Administrative Officer at the world-renowned Cleveland Clinic for more than a decade. Under the Office of the Chief of Staff, she had operational and financial oversight of 23,000 employees and 25 clinical institutes at over 190 sites, while generating $5.5B in annual revenue. Cynthia was also part of the executive team that led the transition to be the first hospital system completely organized around patient needs with the formation of Institutes.

Cynthia’s leadership and impact in the industry have been recognized with dozens of awards including Modern Healthcare’s “Top 25 Women Leaders” and “100 Most Influential People”, Becker’s Hospital Review’s “Top Women Leaders”, and Pittsburgh Business Times “Outstanding CEOs and Top Executives”.

Winfred Parnell
Dr. Winfred Parnell

Dr. Winfred Parnell was appointed to the Nomination and Governance Committee in June 2023. He is a board-certified physician in obstetrics and gynecologic care bringing more than 20 years of board experience and expertise in strategic planning, governance, cultural transformation, regulatory & compliance, quality of care, and crisis management. The practice he founded cares for more than 3,500 women each year. He served as Chairman of the $2.3 billion Parkland Health and Hospital System during a period of transformation, overseeing the organization’s remediation of significant regulatory and compliance weaknesses. He serves on the board of private equity-backed SCA Pharm, one of the largest compounding pharmacies in the country. Dr. Parnell previously served as Chair of the Department of Obstetrics and Gynecology, Chair of the Department of Surgery, and President of the Medical Staff at Medical City Hospital in Dallas.

Dr. Parnell has additional experience serving on the boards of United Way of Dallas, Medical City Hospital, BBVA Compass Bank Board, Texas Healthcare Trustee, Parkland Center for Clinical Innovation, and the American Hospital Association.

In 2008, Dr. Parnell served on the Senator Obama health care Committee and was named a Delegate the Democratic National Convention. He is a graduate of Florida A&M University and received his MD from the University of Florida College of Medicine. He completed his internship and residency training at Parkland Hospital in Dallas, TX. and holds an Executive Certificate in Non-Profit Governance.

Jane Pine Wood
Jane Pine Wood

Jane Pine Wood serves as Counsel in McDonald Hopkins' national Healthcare Practice Group, residing in Massachusetts and representing clients across the country, working remotely for the Cleveland office of McDonald Hopkins. She has 38 years of experience representing clinical, molecular and anatomic laboratories, pathology providers, hospitals, health systems, physicians, and other healthcare providers in corporate, regulatory, reimbursement, contractual, and other matters.

 Jane was previously a Member at McDonald Hopkins, and returned to the firm in 2024 after serving for almost eight years as Chief Legal Counsel for BioReference Health, LLC, the fourth largest laboratory in the United States. She was recruited to this executive leadership role to establish the Legal and Compliance Departments and serve on the Executive Committee. In addition to her Chief Legal Counsel role, Jane served as Chief Compliance Officer from 2016 to 2017, served as head of the Payer Relations Department from 2016 through 2018, and then reassumed leadership of the department in January 2023.

During her original time at McDonald Hopkins, Jane served on the firm's Board of Directors and was instrumental in building one of the largest laboratory and pathology client bases in the nation. She also previously served as an associate attorney at a Nashville-based law firm.  Jane is the President of the New York State Clinical Laboratory Association.  She was elected as a member of the Board of Directors of Aspira Women’s Health, Inc. in 2025, has served as a member of the Board of Directors of the American Pathology Foundation since 2012, and was a member of the Board of Directors of Emmaus Medical, Inc. from 2020 to 2022. Jane holds a BA from Texas A&M University and a Juris Doctorate from Vanderbilt University School of Law.